135 related articles for article (PubMed ID: 25488594)
1. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
Brennan BJ; Poirier A; Moreira S; Morcos PN; Goelzer P; Portmann R; Asthappan J; Funk C; Smith PF
Clin Pharmacokinet; 2015 May; 54(5):537-49. PubMed ID: 25488594
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
[TBL] [Abstract][Full Text] [Related]
3. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Reddy MB; Chen Y; Haznedar JO; Fretland J; Blotner S; Smith P; Tran JQ
Clin Pharmacokinet; 2012 Jul; 51(7):457-65. PubMed ID: 22624502
[TBL] [Abstract][Full Text] [Related]
4. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
5. Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Morcos PN; Chang L; Navarro M; Chung D; Smith PF; Brennan BJ; Tran JQ
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):103-11. PubMed ID: 24290411
[TBL] [Abstract][Full Text] [Related]
6. Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Moreira SA; Morcos PN; Navarro MT; Bech N; Smith PF; Brennan BJ
Pharmacotherapy; 2014 Mar; 34(3):220-6. PubMed ID: 23946152
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
9. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
[TBL] [Abstract][Full Text] [Related]
10. Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
Morcos PN; Moreira SA; Navarro MT; Bech N; Quatkemeyer A; Smith PF; Brennan BJ
J Pharm Pharmacol; 2014 Jan; 66(1):23-31. PubMed ID: 24117531
[TBL] [Abstract][Full Text] [Related]
11. Danoprevir: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Aug; 78(12):1271-1276. PubMed ID: 30117020
[TBL] [Abstract][Full Text] [Related]
12. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Everson G; Cooper C; Hézode C; Shiffman ML; Yoshida E; Beltran-Jaramillo T; Andreone P; Bruno S; Ferenci P; Zeuzem S; Brunda M; Le Pogam S; Nájera I; Zhou J; Navarro MT; Voulgari A; Shulman NS; Yetzer ES
Liver Int; 2015 Jan; 35(1):108-19. PubMed ID: 24517252
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
14. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
Chen H; Zhang Z; Wang L; Huang Z; Gong F; Li X; Chen Y; Wu JJ
Medicine (Baltimore); 2020 Nov; 99(48):e23357. PubMed ID: 33235105
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Kempf DJ; Klein C; Chen HJ; Klein LL; Yeung C; Randolph JT; Lau YY; Chovan LE; Guan Z; Hernandez L; Turner TM; Dandliker PJ; Marsh KC
Antivir Chem Chemother; 2007; 18(3):163-7. PubMed ID: 17626600
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
[TBL] [Abstract][Full Text] [Related]
18. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Eley T; Garimella T; Li W; Bertz RJ
Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
[TBL] [Abstract][Full Text] [Related]
19. Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.
Canini L; Guedj J; Chatterjee A; Lemenuel-Diot A; Smith PF; Perelson AS
Antivir Ther; 2016; 21(4):297-306. PubMed ID: 26555159
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
